KLRC1 and neoplasm: Innate ICIs achieve anti-tumor purposes by targeting checkpoints such as SIRPα, TIGIT, PVRIG, LILRB2, NKG2A, LAG-3, TIM-3, VISTA and CD32B (Table 1; Figure 2A) [84].